DIAGNOS enters the retinal diagnostics market with its new 3D image analysis technology
BROSSARD, Quebec, Oct. 27, 2022 (GLOBE NEWSWIRE) — DIAGNOS inc. (“ DIAGNOSTICS “, the ” Company or “we”) (TSX Venture Exchange: ADK) (OTCQB: DGNOF), a leader in the early detection of serious health conditions through its artificial intelligence (AI) technology FLHAVERE, is proud to announce its entry into the growing retinal diagnostics market, armed with its new 3D image analysis technology.
DIAGNOS pushes the boundaries of practice with deep learning technology capable of diagnosing retinal conditions such as age-related macular degeneration, diabetic retinopathy, glaucoma, macular edema, retinal cancer and other retinal and macular diseases. Additionally, neurological and systemic diseases affecting other parts of the body can also be identified, including Alzheimer’s disease, cardiovascular disease, multiple sclerosis, Parkinson’s disease, and more.
The multimodal data analysis tools developed by DIAGNOS benefit from the most recent advances in ophthalmic science. Combining data extracted from retinal images and optical coherence tomography (OCT) scans, DIAGNOS uses the most accurate technologies available for retinal diagnosis. This technology is more precise than MRI and ultrasound, it is non-invasive and allows the production of 3D cross-sectional images of the retina”.
“Growing interest in advanced retinal imaging systems by the healthcare industry, the adoption of healthcare reimbursement policies in several regions, and the changing regulatory environment are some of the factors that drove us to make the decision to enter the retinal diagnostics market,” said Mr. André Larente, President of DIAGNOS. “Two of our main competitors recently received investments of $50M and $26M respectively following their decision to enter the retinal diagnostics market, which certainly speaks volumes about the potential of this category”.
Technological advancements in diagnostic methods, rapidly changing healthcare infrastructure, increasing adoption of advanced retinal imaging systems, and favorable healthcare reimbursement policies are contributing to the rapid growth of this category, which should become the gold standard of the future in the successful management of retinal disorders.
DIAGNOS is a publicly traded Canadian company whose mission is the early detection of serious health problems by leveraging its artificial intelligence (AI) platform FLAIRE. FLAIRE allows you to quickly modify and develop applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier to analyze retinal images. CARA is a low-cost tool used for real-time screening of a high volume of patients. CARA has been cleared for sale by the following regulatory bodies; Health Canada, FDA (United States), CE (Europe), COFEPRIS (Mexico), and Saudi FDA (Saudi Arabia).
Further information is available on the websites www.diagnos.com and www.sedar.com.
For more information on this press release, please contact:
Mr. André Larente, President
Tel: 450-678-8882, extension 224
Email: [email protected]
This press release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
A photo associated with this press release is available at: